跳至主要内容
临床试验/RBR-4tg72t
RBR-4tg72t进行中(未招募)未知

The use of intermittent Ascorbic Acid in the prevention of central venous catheter obstruction in pediatrics

Complexo do Hospital de Clínicas da Universidade Federal do Paraná0 个研究点开始时间: 2020年7月27日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
28D 至 14Y(—)

入选标准

  • Children between 28 days and 13 years 11 months and 29 days will be included in the study, using a single or double lumen central venous catheter, with the consent of the parents and/or guardians by signing the Free and Informed Consent Term - TCLE added to the Free and Informed Consent Term and that are not accompanied by serum bilirubin dosage

排除标准

  • Will be excluded from the study: Carriers of nephrological diseases, clotting disorders and/or hemochromatosis; research subjects with parents under 18 years of age; research subjects whose guardians do not consent to or withdraw from the CLT; research subjects whose do not consent to or withdraw from the CLT; children with bilirubin dosage; newborns under 28 days of age; fully implanted catheter carriers; entry of medicines incompatible with ascorbic acid (etomidate, propofol, tipental, amikacin, vancomycin)

研究者

发起方
Complexo do Hospital de Clínicas da Universidade Federal do Paraná

相似试验